Receive updates from Psychedelics Today for free, starting right now.
We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.
This way you won't miss any new article from Psychedelics Today. Unsubscribe at any time.
Site title: Expert-informed media and education | Psychedelics Today
Is this your feed? Claim it!
Devon Phillips, partnerships manager at MAPS, argues that people rarely change because they got better information. They change when it arrives through someone they already trust. A case for meeting curiosity where it starts, in music, community spaces, and culture, before it turns into an uninformed experience.
The post
A donor gift with no diagnosis requirement forced a debate inside Thank You Life. Its executive director asks whether documented suffering should remain the price of admission to psychedelic care.
The post Who Gets to Heal? appeared first on
Oregon's psilocybin program posted its first real-world outcome data this week, just as regulators move on fee increases that operators say could close the market. Plus Trump's FDA nominee and Johnson & Johnson's bet on neuroplastogens.
The post
Please join us this autumn for the 19th Horizons conference on October 15-17 in New York City. This is one of the important annual gatherings for the field of psychedelics, and best chances to meet old friends and new colleagues in-person. Register soon to enjoy steep discounts over autumn prices.
The post
Resilient Pharmaceuticals has resubmitted its New Drug Application for MDMA-assisted therapy for PTSD, without the new Phase 3 trial the FDA asked for. Canada funds a C$24 million cannabis and brain health consortium, and Definium's oral LSD tablet clears Phase 3 in generalized anxiety disorder.
The post